With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14

Mammoth Biosciences set out to develop CRISPR-based diagnostics that could be faster and cheaper than what’s available today. Those diagnostics are still on the way, but Mammoth now has a new piece in its toolbox that could broaden the reach of these tests and expand the startup into therapeutic applications. To support development of these […]

Click to view original post